Immunic, Inc. (IMUX)
| Market Cap | 162.10M +51.0% |
| Revenue (ttm) | n/a |
| Net Income | -97.17M |
| EPS | -6.24 |
| Shares Out | 13.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 155,039 |
| Open | 11.99 |
| Previous Close | 12.00 |
| Day's Range | 11.45 - 12.10 |
| 52-Week Range | 5.06 - 15.10 |
| Beta | 1.21 |
| Analysts | Strong Buy |
| Price Target | 36.00 (+202.52%) |
| Earnings Date | May 14, 2026 |
About IMUX
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patien... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for IMUX stock is "Strong Buy." The 12-month stock price target is $36.0, which is an increase of 202.52% from the latest price.
News
Immunic initiated with an Outperform at LifeSci Capital
LifeSci Capital analyst Sam Slutsky initiated coverage of Immunic (IMUX) with an Outperform rating and $56 price target
Immunic to Participate in Investor and Medical Conferences in May
NEW YORK, April 30, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced ...
Immunic price target adjusted to $22 from $5 at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield adjusted the firm’s price target on Immunic (IMUX) to $22 from $5 and keeps a Buy rating on the shares. The firm cites the company’s…
Immunic CMO Andreas Muehler to depart, Michael Panzara to succeed
Immunic (IMUX) announced the appointment of Michael Panzara as chief medical officer, effective April 24. Panzara will lead the company’s development organization, including clinical development, medi...
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.
– Proven Leader in Neurology Drug Development, Including for Several Approved MultipleSclerosis Therapies – – Strong Experience in Advancing Late-Stage Clinical Programs and Obtaining Global Regulator...
Immunic trading halted, news pending
19:50 EDT Immunic (IMUX) trading halted, news pending
Immunic announces 1-for-10 reverse stock split
Immunic (IMUX) announced that it will effect a reverse stock split of its outstanding shares of common stock, effective as of 12:01 a.m. Eastern Time on April 27. Immunic’s common…
Immunic, Inc. Announces 1-for-10 Reverse Stock Split
NEW YORK, April 23, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the "Company" or ...
Immunic initiated with a Buy at Stifel
Stifel initiated coverage of Immunic (IMUX) with a Buy rating and $2.50 price target The cites a belief that vidoflimus calcium has a high probability-of-success in Phase 3 RMS studies…
Immunic downgraded to Hold from Buy at D. Boral Capital
D. Boral Capital analyst Jason Kolbert downgraded Immunic (IMUX) to Hold from Buy without a price target The company is moving toward a reverse stock split, which is negative for…
Immunic to Participate in Scientific and Medical Conferences in April
NEW YORK, April 9, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced p...
Immunic files to sell 458.15M shares of common stock for holders
16:33 EDT Immunic (IMUX) files to sell 458.15M shares of common stock for holders
Immunic regains compliance with Nasdaq
Immunic (IMUX) announced that it received written notice from Nasdaq on March 27 informing the company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing…
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
NEW YORK, April 1, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced t...
Immunic appoints Mineralys Therapeutics CEO Jon Congleton to board
Immunic (IMUX) announced the appointment of Jon Congleton to its board of directors, effective March 27. Congleton currently serves as CEO and member of the board of directors of Mineralys…
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
– Nearly 40-Year Biopharmaceutical Professional with Deep CNS and Commercial Leadership Experience in Multiple Sclerosis – – Served on Original Team Responsible for the Launch of Copaxone® in the Unit...
Immunic initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Immunic (IMUX) with a Buy rating and $7 price target The company is advancing vidofludimus calcium, an oral multiple sclerosis therapy that combines “validated” DHODH ...
Immunic Transcript: Stifel 2026 Virtual CNS Forum
2026 is set to be pivotal with phase III RMS data and NDA submission preparations. Vidofludimus calcium offers a unique safety and neuroprotective profile, targeting both relapsing and progressive MS, with strong clinical data and significant commercial potential.
Immunic Transcript: Leerink Global Healthcare Conference 2026
Vidofludimus Calcium offers a unique dual mechanism for MS, showing strong efficacy and safety in phase II trials. Phase III studies in relapsing MS are fully enrolled and expected to read out by year-end, while a pivotal PPMS trial is set to launch, targeting a multi-billion-dollar market opportunity.
Immunic gets European patent for vidofludimus calcium
Immunic (IMUX) announced that the European Patent Office has granted a key European patent, EP3713554, directed to label-relevant dosing regimens of lead asset, nuclear receptor-related 1 activator, v...
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
– Patent Covers Label-Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 – – Broad Protection Extends to All Forms of Vidofludimus, In...
Immunic to Participate in Investor Conferences in March
NEW YORK, March 3, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal disease...
Immunic price target lowered to $5 from $8 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Immunic (IMUX) to $5 from $8 and keeps a Buy rating on the shares. The firm updated the company’s model. Published first…
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 – – Raised Proceeds of $200 Million in a Private Placement, with Potential ...
Immunic Announces Closing of Oversubscribed Private Placement Financing
– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – – Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiat...